Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

Brier, Matthew R.; Gordon, Brian A.; Friedrichsen, Karl A.; McCarthy, John E.; Stern, Ari; Christensen, Jon; Owen, Christopher G.; Aldea, Patricia; Su, Yi; Hassenstab, Jason; Cairns, Nigel J.; Holtzman, David M.; Fagan, Anne M.; Morris, John C.; Benzinger, Tammie L.S.; Ances, Beau M.

doi:10.1126/scitranslmed.aaf2362

articleScience Translational MedicineMay 11, 2016GREEN OA

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

MRMatthew R. Brier BABrian A. Gordon KAKarl A. Friedrichsen JEJohn E. McCarthy ASAri Stern

Washington University in St. Louis · Hope Center for Neurological Disorders

PubMed

Indexed incrossrefpubmed

Abstract

Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary tangles, neuritic plaques, and neuropil threads. Until recently, only Aβ could be studied in humans using positron emission tomography (PET) imaging owing to a lack of tau PET imaging agents. Clinical pathological studies have linked tau pathology closely to the onset and progression of cognitive symptoms in patients with AD. We report PET imaging of tau and Aβ in a cohort of cognitively normal older adults and those with mild AD. Multivariate analyses identified unique disease-related stereotypical spatial patterns (topographies) for…

Citation impact

740

total citations

FWCI: 51.17
Percentile: 100%
References: 57

Citations per year

Authors

16

Topics & keywords

Topics

Keywords

Neuroscience
Disease
Cognition
Alzheimer's disease
Neuroimaging
Cognitive reserve
Medicine
Psychology

No related works found for this paper.